# Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

> **NCT01376557** · PHASE2 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 299 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 75 mg LX4211
- **DRUG:** 200 mg LX4211
- **DRUG:** 400 mg LX4211
- **DRUG:** 200 mg LX4211
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01376557
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376557, "Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01376557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*